Patents by Inventor Eiko UNO

Eiko UNO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ROR1-positive mesenchymal stem cells and method for preparing same, pharmaceutical composition containing ROR1-positive mesenchymal stem cells and method for preparing same, and method for preventing or treating disease using ROR1-positive mesenchymal stem cells
    Patent number: 11707488
    Abstract: An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects against various diseases, a novel pharmaceutical composition containing these mesenchymal stem cells, and a method for preparing the same. The present invention relates to ROR1-positive mesenchymal stem cells. The ROR1-positive mesenchymal stem cells are preferably positive for CD29, CD73, CD90, CD105 and CD166 and are derived from umbilical cord or adipose tissue.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: July 25, 2023
    Assignee: ROHTO PHARMACEUTICAL CO., LTD.
    Inventors: Yoshifumi Ikeyama, Hiroyuki Nishida, Tomohiro Tsuda, Eiko Uno, Masayo Yumoto, Kazuma Suda, Mihoko Yoshino, Xuan Trung Ngo
  • Method for treating a disease, comprising administering mesenchymal stem cells or culture supernatant thereof to a subject
    Patent number: 11179420
    Abstract: An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects for various diseases, a novel pharmaceutical composition containing the mesenchymal stem cells, and methods for preparing these. The present invention provides mesenchymal stem cells expressing at least one cell surface marker selected from the group consisting of CD201, CD46, CD56, CD147 and CD165. The mesenchymal stem cells expressing such a specific marker are positive for CD29, CD73, CD90, CD105 and CD166, and maintain an undifferentiated state.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: November 23, 2021
    Assignee: ROHTO PHARMACEUTICAL CO., LTD.
    Inventors: Yoshifumi Ikeyama, Eiko Uno, Masayo Yumoto, Mihoko Yoshino, Xuan Trung Ngo, Hiroyuki Nishida, Akiko Uetani
  • ROR1-POSITIVE MESENCHYMAL STEM CELL-CONTAINING PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASE ASSOCIATED WITH FIBROSIS, METHOD FOR PREPARING SAME, AND METHOD FOR PREVENTING OR TREATING DISEASE ASSOCIATED WITH FIBROSIS USING ROR1-POSITIVE MESENCHYMAL STEM CELLS
    Publication number: 20200069740
    Abstract: The purpose of the present invention is to provide the following: novel mesenchymal stem cells having an excellent therapeutic effect on various diseases, particularly diseases associated with fibrosis; and a pharmaceutical composition containing such mesenchymal stem cells. The present invention is a therapeutic agent for fibrosis that contains ROR1-positive mesenchymal stem cells and/or a culture supernatant thereof and that is for preventing or treating a disease associated with fibrosis. The mesenchymal stem cells are CD29-, CD73-, CD90-, CD105-, and CD166-positive and are preferably derived from the umbilical cord or fat. In addition, the abovementioned disease associated with fibrosis is preferably a liver disease, a lung disease, a kidney disease, or a heart disease.
    Type: Application
    Filed: March 8, 2018
    Publication date: March 5, 2020
    Applicant: ROHTO PHARMACEUTICAL CO., LTD.
    Inventors: Hikari Hasegawa, Masayo Yumoto, Yoshifumi Ikeyama, Hiroyuki Nishida, Tomohiro Tsuda, Eiko Uno, Kazuma Suda, Mihoko Yoshino, Xuan Trung Ngo
  • MESENCHYMAL STEM CELL EXPRESSING AT LEAST ONE CELL SURFACE MARKER SELECTED FROM THE GROUP CONSISTING OF CD201, CD46, CD56, CD147, AND CD165, METHOD FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITION CONTAINING THE MESENCHYMAL STEM CELLS, AND METHOD FOR PREPARING THE SAME
    Publication number: 20190117701
    Abstract: An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects for various diseases, a novel pharmaceutical composition containing the mesenchymal stem cells, and methods for preparing these. The present invention provides mesenchymal stem cells expressing at least one cell surface marker selected from the group consisting of CD201, CD46, CD56, CD147 and CD165. The mesenchymal stem cells expressing such a specific marker are positive for CD29, CD73, CD90, CD105 and CD166, and maintain an undifferentiated state.
    Type: Application
    Filed: April 27, 2017
    Publication date: April 25, 2019
    Applicant: ROHTO PHARMACEUTICAL CO., LTD.
    Inventors: Yoshifumi Ikeyama, Eiko Uno, Masayo Yumoto, Mihoko Yoshino, Xuan Trung Ngo, Hiroyuki Nishida, Akiko Uetani
  • ROR1-POSITIVE MESENCHYMAL STEM CELLS AND METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITION CONTAINING ROR1-POSITIVE MESENCHYMAL STEM CELLS AND METHOD FOR PREPARING SAME, AND METHOD FOR PREVENTING OR TREATING DISEASE USING ROR1-POSITIVE MESENCHYMAL STEM CELLS
    Publication number: 20180333436
    Abstract: An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects against various diseases, a novel pharmaceutical composition containing these mesenchymal stem cells, and a method for preparing the same. The present invention relates to ROR1-positive mesenchymal stem cells. The ROR1-positive mesenchymal stem cells are preferably positive for CD29, CD73, CD90, CD105 and CD166 and are derived from umbilical cord or adipose tissue.
    Type: Application
    Filed: August 29, 2016
    Publication date: November 22, 2018
    Applicant: ROHTO PHARMACEUTICAL CO., LTD.
    Inventors: Yoshifumi Ikeyama, Hiroyuki Nishida, Tomohiro Tsuda, Eiko Uno, Masayo Yumoto, Kazuma Suda, Mihoko Yoshino, Xuan Trung Ngo
  • Method for breeding plant having self-compatibility
    Patent number: 9988639
    Abstract: The problem of providing a technology that converts a Brassica rapa plant having self-incompatibility to having self-compatibility is addressed. The problem is solved by causing a pollen factor (SP11) to be inactive at a self-incompatibility gene locus for a Brassica rapa plant, while maintaining the inverted repeat sequence (SMI) on a class I dominant S haplotype.
    Type: Grant
    Filed: January 20, 2014
    Date of Patent: June 5, 2018
    Assignee: NATIONAL UNIVERSITY CORPORATION NARA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Seiji Takayama, Eiko Uno
  • MESENCHYMAL STEM CELL CULTURE MEDIUM, METHODS FOR CULTURING MESENCHYMAL STEM CELLS, AND MESENCHYMAL STEM CELLS
    Publication number: 20180066231
    Abstract: The present invention aims to provide a mesenchymal stem cell culture medium suitable for culturing umbilical cord mesenchymal stem cells in particular, among the mesenchymal stem cells. The present invention is of a mesenchymal stem cell culture medium comprising at least 2 kinds of components selected from the group consisting of a PTEN inhibitor, a p53 inhibitor, a p38 inhibitor, an Wnt signal activator and a ROCK inhibitor as well as basal medium for culturing animal cells.
    Type: Application
    Filed: February 26, 2016
    Publication date: March 8, 2018
    Applicant: ROHTO PHARMACEUTICAL CO., LTD.
    Inventors: Yoshifumi IKEYAMA, Toru OKUBO, Hiroyuki NISHIDA, Tomohiro TSUDA, Eiko UNO, Masayo YUMOTO
  • METHOD FOR BREEDING BRASSICA RAPA PLANT HAVING SELF-COMPATIBILITY
    Publication number: 20150353946
    Abstract: The problem of providing a technology that converts a Brassica rapa plant having self-incompatibility to having self-compatibility is addressed. The problem is solved by causing a pollen factor (SP11) to be inactive at a self-incompatibility gene locus for a Brassica rapa plant, while maintaining the inverted repeat sequence (SMI) on a class I dominant S haplotype.
    Type: Application
    Filed: January 20, 2014
    Publication date: December 10, 2015
    Inventors: Seiji TAKAYAMA, Eiko UNO